Advancing Bispecifics and Combination Therapy to the Clinic track banner

 

T cell engagement continues to be a focus for bispecific investigators, many of whom are looking for superiority in terms of low cytokine release, improved potency and specificity, and longer half-life. After initial excitement with the checkpoint inhibitors, it is clear that bispecifics and complementary combinations are the way forward. Many of these combine blockade with approaches that enhance the immune response, overcome suppressor mechanisms and encourage infiltration of immune cells to the tumour. Currently there is increased interest in bispecific cytokines, especially ones that demonstrate improved properties and a balance between safety and efficacy. The link between preclinical and clinical is complex and investigators are addressing the many safety factors to consider.

Coverage will include, but is not limited to:

 

  • Bispecifics and combinations of checkpoint inhibitors with, for example, agonists, cytokines, VEGF inhibitors and small molecules
  • Co-stimulatory bispecifics
  • Improved T cell engagers
  • Bispecifics with cytokines
  • Advances with CD47 bispecifics
  • Bispecific engagement of NK cells
  • Effective non-bispecific combination therapies
  • Bispecifics for a range of indications, not only cancer
  • Preclinical and clinical results including predictive studies, proof-of concept, and data from advanced products

If you would like to submit a proposal to give a presentation at this meeting, please click here.

 

The deadline for priority consideration is 10 April 2020.

 

All proposals are subject to review by session chairpersons and/or the Scientific Advisory Committee to ensure the overall quality of the conference program. Additionally, as per Cambridge Healthtech Institute’s policy, a select number of vendors and consultants who provide products and services will be offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.

For more details on the conference, please contact:
Nicole Lyscom PhD

Senior Conference Director

Cambridge Healthtech Institute

Phone: (+1) +44 7791 866489
Email: nlyscom@helathtech.com

 

For partnering and sponsorship information, please contact:

Companies A-K

Jason Gerardi
Senior Manager, Business Development

Cambridge Healthtech Institute
Phone: (+1) 781.972.5452
Email: jgerardi@healthtech.com

 

Companies L-Z

Ashley Parsons
Manager, Business Development

Cambridge Healthtech Institute
Phone: (+1) 781.972.1340
Email: ashleyparsons@healthtech.com